^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CART22

    i
    Associations
    News

    Trials

    Company:
    University of Pennsylvania
    Drug class:
    CD22-targeted CAR-T immunotherapy
    Related drugs:
    Associations
    News

    Trials

    Apply
    CART22 Alone or in Combination With huCART19 for ALL (NCT03620058)
    Phase 1
    University of Pennsylvania
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    09/27/2018
    Primary completion :
    01/01/2036
    Completion :
    01/01/2036
    CD22
    |
    CD22 expression
    |
    CART22 • huCART19
    CD22 Redirected Autologous T Cells for ALL (NCT02650414)
    Phase 1
    University of Pennsylvania
    Recruiting
    Last update posted :
    02/05/2024
    Initiation :
    01/13/2016
    Primary completion :
    12/01/2037
    Completion :
    12/01/2037
    CD22
    |
    CD22 expression
    |
    CART22
    Co-administration of CART22-65s and huCART19 for B-ALL (NCT05674175)
    Phase 1/2
    Stephan Grupp MD PhD
    Recruiting
    Last update posted :
    12/19/2023
    Initiation :
    01/25/2023
    Primary completion :
    01/15/2027
    Completion :
    01/15/2029
    CD22
    |
    CD19 expression • CD22 expression
    |
    Kymriah (tisagenlecleucel-T) • CART22 • huCART19